Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Rises By 5.4%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 3,690,000 shares, an increase of 5.4% from the July 31st total of 3,500,000 shares. Based on an average daily volume of 340,900 shares, the short-interest ratio is currently 10.8 days.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC boosted its holdings in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in Ascendis Pharma A/S by 1.1% during the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock worth $616,050,000 after buying an additional 44,580 shares in the last quarter. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after buying an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after buying an additional 336,976 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Ascendis Pharma A/S by 5.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after buying an additional 93,185 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have commented on ASND shares. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Wednesday, May 15th. TD Cowen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and upped their target price for the stock from $156.00 to $175.00 in a research report on Tuesday, June 25th. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They issued a “buy” rating and a $200.00 target price for the company. Finally, Morgan Stanley upped their target price on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $185.00.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $138.45 on Tuesday. The stock has a market capitalization of $8.06 billion, a PE ratio of -14.41 and a beta of 0.63. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The firm has a 50 day simple moving average of $135.34 and a 200-day simple moving average of $138.89.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.